- Home
- PSHG vs TNXP Comparison
PSHG vs TNXP Comparison
Compare PSHG & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- TNXP
- Stock Information
- Founded
- PSHG 2010
- TNXP 2007
- Country
- PSHG Greece
- TNXP United States
- Employees
- PSHG N/A
- TNXP N/A
- Industry
- PSHG Marine Transportation
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- TNXP Health Care
- Exchange
- PSHG Nasdaq
- TNXP Nasdaq
- Market Cap
- PSHG 24.2M
- TNXP 19.5M
- IPO Year
- PSHG N/A
- TNXP N/A
- Fundamental
- Price
- PSHG $1.94
- TNXP $0.13
- Analyst Decision
- PSHG Strong Buy
- TNXP Strong Buy
- Analyst Count
- PSHG 1
- TNXP 2
- Target Price
- PSHG $6.50
- TNXP $53.50
- AVG Volume (30 Days)
- PSHG 71.0K
- TNXP 13.8M
- Earning Date
- PSHG 11-07-2024
- TNXP 11-12-2024
- Dividend Yield
- PSHG N/A
- TNXP N/A
- EPS Growth
- PSHG N/A
- TNXP N/A
- EPS
- PSHG 1.51
- TNXP N/A
- Revenue
- PSHG $89,608,000.00
- TNXP $11,291,000.00
- Revenue This Year
- PSHG N/A
- TNXP $62.53
- Revenue Next Year
- PSHG $2.66
- TNXP $26.17
- P/E Ratio
- PSHG $1.29
- TNXP N/A
- Revenue Growth
- PSHG N/A
- TNXP 183.05
- 52 Week Low
- PSHG $1.70
- TNXP $0.12
- 52 Week High
- PSHG $2.58
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- PSHG 45.55
- TNXP 33.87
- Support Level
- PSHG $1.95
- TNXP $0.13
- Resistance Level
- PSHG $2.04
- TNXP $0.15
- Average True Range (ATR)
- PSHG 0.08
- TNXP 0.01
- MACD
- PSHG -0.01
- TNXP 0.00
- Stochastic Oscillator
- PSHG 33.87
- TNXP 4.86
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.